Endocrinology SMART on FHIR Prior Auth: In-EMR Automation for High-Volume Medications

Klivira's SMART on FHIR Prior Auth solution for endocrinology integrates directly into your EMR, automating the complex approval process for high-volume medications and devices like GLP-1s, CGMs, and insulin pumps.

Revenue cycle directors and prior authorization coordinators in endocrinology face unique challenges, including high PA volumes for diabetes and obesity medications, and variable payer coverage. Manual workflows lead to significant clinician burden, context-switching, and delays. Klivira addresses these by embedding prior auth directly into the clinical workflow, leveraging SMART on FHIR standards.

The Challenge: High-Volume Endocrinology PAs and Manual Workflows

Endocrinology practices manage a substantial volume of prior authorizations, particularly for GLP-1 agonists (e.g., Ozempic, Mounjaro, Zepbound), Continuous Glucose Monitors (CGMs), insulin pumps, and growth hormone therapy. These PAs often require extensive clinical documentation, adherence to payer-specific criteria, and frequent re-authorization cycles, creating a significant administrative load outside the EMR.

Key Prior Authorization Triggers in Endocrinology

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for T2D and obesity indications.
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) for T2D, heart failure, and CKD.
Continuous Glucose Monitoring (CGM) systems (e.g., Dexcom G7, FreeStyle Libre 3).
Insulin pumps and tubeless systems (e.g., Tandem t:slim X2, Omnipod 5).
Growth hormone therapy (e.g., somatropin biosimilars).

Klivira's SMART on FHIR Solution for Endocrinology

Klivira integrates seamlessly into your existing EMR (Epic, Cerner, athenahealth, MEDITECH) via SMART on FHIR. This allows clinicians to launch the prior authorization workflow directly from the patient chart, eliminating context-switching and manual data entry. By leveraging FHIR R4, Klivira automatically pulls relevant clinical data, such as A1c, BMI, medication history, and diagnostic codes, directly from the EMR, streamlining documentation for complex endocrinology PAs.

Automating Documentation and Reducing Denial Risk

Endocrinology PAs often require adherence to guidelines from bodies like ADA, AACE, and ATA. Klivira's platform incorporates guideline-aware logic and payer-specific criteria for GLP-1 indications (T2D vs. obesity), CGM coverage (insulin-requiring status), and insulin pump adherence. Automated data extraction via FHIR minimizes documentation gaps, addresses common denial reasons like step therapy non-compliance or missing BMI criteria, and supports biosimilar substitution requirements.

SMART on FHIR Benefits for Endocrinology PA Workflows

**In-EMR Workflow**: Launch PA directly from Epic Hyperspace, Cerner PowerChart, or athenaOne, eliminating context-switching.
**Automated Data Capture**: FHIR R4 reads US Core resources to populate PA forms, reducing manual transcription errors.
**Da Vinci PAS Integration**: Supports standardized electronic prior authorization submission for faster decisions.
**Structured Write-back**: PA decisions and status updates are written back to the EMR as DocumentReference, Communication, or Task resources.
**High-Volume Efficiency**: Addresses the administrative burden of GLP-1, CGM, and insulin pump re-authorizations.

Addressing Specialty-Specific Workflow Constraints

Klivira's platform is designed to handle the unique demands of endocrinology. This includes managing the high GLP-1 PA volume driven by rapid market adoption, streamlining CGM re-authorization cycles with adherence documentation, and coordinating hybrid closed-loop system PAs. Our policy engine tracks variable payer coverage for obesity medications, ensuring accurate routing and submission.

Frequently asked questions

How does SMART on FHIR specifically help with GLP-1 prior authorization in endocrinology?

For GLP-1 PAs, Klivira's SMART on FHIR integration automatically pulls critical data like A1c, BMI, and prior medication trials from the EMR. This ensures all required documentation per ADA/AACE guidelines and payer-specific criteria (e.g., T2D vs. obesity indications, step therapy compliance) is accurately included, reducing manual effort and denial rates.

What EMRs does Klivira's SMART on FHIR prior auth solution integrate with for endocrinology practices?

Klivira's SMART on FHIR solution integrates with major EMR systems commonly used in endocrinology, including Epic, Cerner, athenahealth, and MEDITECH. This allows for a consistent in-EMR prior authorization experience regardless of your specific EMR environment.

Can Klivira's SMART on FHIR workflow handle re-authorization for devices like CGMs and insulin pumps?

Yes, Klivira supports the re-authorization cycles for devices like CGMs and insulin pumps. The SMART on FHIR integration facilitates the automated retrieval of adherence documentation and other required clinical context directly from the EMR, streamlining the periodic re-approval process for ongoing patient care.

What Da Vinci standards are utilized in Klivira's SMART on FHIR for endocrinology prior auth?

Klivira leverages the full suite of Da Vinci Implementation Guides, including Da Vinci CRD for coverage requirements discovery, Da Vinci DTR for documentation templates and rules, and Da Vinci PAS for electronic prior authorization submission. These standards ensure a robust and interoperable PA workflow within your endocrinology practice.

Does the SMART on FHIR integration address common denial reasons for endocrinology PAs?

Yes, by automating data collection and adhering to payer-specific rules and clinical guidelines, the SMART on FHIR integration significantly reduces common denial reasons. This includes issues like GLP-1 obesity-indication coverage gaps, step therapy non-compliance, CGM denial for non-insulin-requiring T2D, and missing BMI criteria, by ensuring complete and accurate submissions.